Desvenlafaxine is a serotonin and norepinephrine reuptake inhibitor indicated for the treatment of adults with major depressive disorder (MDD). It is available as extended-release tablets for oral use. MedsAcross supplies Desvenlafaxine for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
From the regulator-approved product information. Each section names its source.
PRISTIQ is indicated for the treatment of adults with major depressive disorder (MDD). PRISTIQ is a serotonin and norepinephrine reuptake inhibitor (SNRI) indicated for the treatment of adults with major depressive disorder (MDD).
Source: US FDA prescribing information
The exact mechanism of the antidepressant action of desvenlafaxine is unknown, but is thought to be related to the potentiation of serotonin and norepinephrine in the central nervous system, through inhibition of their reuptake. Non-clinical studies have shown that desvenlafaxine is a potent and selective SNRI.
Source: US FDA prescribing information
• Recommended dose: 50 mg once daily with or without food. • There was no evidence that doses greater than 50 mg per day confer any additional benefit. • The 25 mg per day dose is intended for a gradual reduction in dose when discontinuing treatment or dosing in severe renal and end-stage renal disease patients. • Discontinuation: Reduce dose gradually whenever possible. • Take tablets whole, do not divide, crush, chew, or dissolve. • Moderate renal impairment: Maximum dose 50 mg per day. • Severe renal impairment and end-stage renal disease: Maximum dose 25 mg per day or 50 mg every other day. • Moderate to severe hepatic impairment: Maximum dose 100 mg per day.
Source: US FDA prescribing information
• Hypersensitivity to desvenlafaxine succinate, venlafaxine hydrochloride or to any excipients in the PRISTIQ formulation. Angioedema has been reported in patients treated with PRISTIQ. • The use of MAOIs intended to treat psychiatric disorders with PRISTIQ or within 7 days of stopping treatment with PRISTIQ is contraindicated because of an increased risk of serotonin syndrome. The use of PRISTIQ within 14 days of stopping an MAOI intended to treat psychiatric disorders is also contraindicated. • Starting PRISTIQ in a patient who is being treated with MAOIs such as linezolid or intravenous methylene blue is also contraindicated because of an increased risk of serotonin syndrome.
Source: US FDA prescribing information
Boxed warning (suicidal thoughts and behaviors): Antidepressants increased the risk of suicidal thoughts and behavior in children, adolescents, and young adults in short-term studies. These studies did not show an increase in the risk of suicidal thoughts and behavior with antidepressant use in patients over age 24, there was a reduction in risk with antidepressant use in patients aged 65 and older. • Serotonin Syndrome: Increased risk when co-administered with other serotonergic agents, but also when taken alone. If it occurs, discontinue PRISTIQ and serotonergic agents and initiate supportive treatment. • Elevated Blood Pressure: Control hypertension before initiating treatment. Monitor blood pressure regularly during treatment. • Increased Risk of Bleeding: Concomitant use of aspirin, NSAIDs, other antiplatelet drugs, warfarin, and other anticoagulants may increase this risk.
Source: US FDA prescribing information
The following adverse reactions are discussed in greater detail in other sections of the label. • Hypersensitivity • Suicidal Thoughts and Behaviors in Pediatric and Young Adult Patients • Serotonin Syndrome • Elevated Blood Pressure • Increased Risk of Bleeding • Angle Closure Glaucoma • Activation of Mania/Hypomania • Discontinuation Syndrome • Seizure • Hyponatremia • Interstitial Lung Disease and Eosinophilic Pneumonia • Sexual Dysfunction Most common adverse reactions (incidence ≥5% and twice the rate of placebo in the 50 or 100 mg dose groups) were: nausea, dizziness, insomnia, hyperhidrosis, constipation, somnolence, decreased appetite, anxiety, and specific male sexual function disorders.
Source: US FDA prescribing information
Drugs Having Clinically Important Interactions with PRISTIQ Table 8: Clinically Important Drug Interactions with PRISTIQ Monoamine Oxidase Inhibitors (MAOI) Clinical Impact The concomitant use of SSRIs and SNRIs including PRISTIQ with MAOIs increases the risk of serotonin syndrome. Intervention Concomitant use of PRISTIQ is contraindicated: • With an MAOI intended to treat psychiatric disorders or within 7 days of stopping treatment with PRISTIQ. • Within 14 days of stopping an MAOI intended to treat psychiatric disorders. • In a patient who is being treated with linezolid or intravenous methylene blue. Examples selegiline, tranylcypromine, isocarboxazid, phenelzine, linezolid, methylene blue Other Serotonergic Drugs Clinical Impact Concomitant use of PRISTIQ with other serotonergic drugs increases the risk of serotonin syndrome.
Source: US FDA prescribing information
Store at 20° to 25°C (68° to 77°F), excursions permitted to 15° to 30°C (59° to 86°F).
Source: US FDA prescribing information
For healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
6 presentations of Desvenlafaxine, sorted by availability.
| Medicine | Manufacturer | Register | Availability |
|---|---|---|---|
| Desvenlafaxine 50 mg extended-release tabletOralGeneric name | — | US FDA | Available on request |
| Desvenlafaxine 100 mg extended-release tabletOralGeneric name | — | US FDA | Available on request |
| Desvenlafaxine 25 mg extended-release tabletOralGeneric name | — | US FDA | Available on request |
| Pristiq Extended-Release 100 mg extended-release tabletOral | Wyeth Pharmaceuticals | US FDA | Available on request |
| Pristiq Extended-Release 50 mg extended-release tabletOral | Wyeth Pharmaceuticals | US FDA | Available on request |
| Pristiq Extended-Release 25 mg extended-release tabletOral | Wyeth Pharmaceuticals | US FDA | Available on request |
1 brand names across 1 markets.
United States
Approval facts from US FDA, EMA and CDSCO data, and registration status by country where we hold register data.
Conditions linked to Desvenlafaxine in public data. This is not a list of approved uses, see the clinical information.
Yes, on request. MedsAcross lists 6 presentations of Desvenlafaxine and sources them for licensed hospitals, importers and physicians against valid import documents.
The catalogue lists 1 brand names for Desvenlafaxine, including Pristiq Extended-Release.
Yes. The US FDA first approved Desvenlafaxine on 29 February 2008, according to Drugs@FDA.
No listed presentation of Desvenlafaxine is recorded as needing a cold chain. Storage conditions are shown on each presentation page.
Desvenlafaxine is classified under ATC code N06AX23 (Desvenlafaxine).
Tell us the strength, quantity and destination country. Our team replies with availability, lead time and the import documents needed.